Cetera Investment Advisers Boosts Stake in Cencora, Inc. $COR

Cetera Investment Advisers lifted its position in Cencora, Inc. (NYSE:COR) by 14.5% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 93,627 shares of the company’s stock after purchasing an additional 11,860 shares during the quarter. Cetera Investment Advisers’ holdings in Cencora were worth $29,412,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Kemnay Advisory Services Inc. acquired a new position in Cencora during the fourth quarter worth approximately $25,000. Oakworth Capital Inc. purchased a new stake in Cencora in the fourth quarter valued at approximately $26,000. Elyxium Wealth LLC acquired a new stake in shares of Cencora in the fourth quarter valued at approximately $27,000. Archer Investment Corp grew its position in shares of Cencora by 134.3% during the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after acquiring an additional 47 shares during the last quarter. Finally, Motiv8 Investments LLC purchased a new position in shares of Cencora during the fourth quarter worth approximately $29,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Price Performance

Cencora stock opened at $309.67 on Monday. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. The business has a 50 day simple moving average of $284.52 and a 200-day simple moving average of $316.29. Cencora, Inc. has a 12 month low of $244.82 and a 12 month high of $377.54. The stock has a market capitalization of $60.25 billion, a PE ratio of 23.75, a price-to-earnings-growth ratio of 1.72 and a beta of 0.58.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The firm had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business’s quarterly revenue was up 3.9% on a year-over-year basis. During the same quarter last year, the business earned $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities analysts predict that Cencora, Inc. will post 17.79 earnings per share for the current year.

Cencora announced that its Board of Directors has authorized a share buyback plan on Thursday, May 21st that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the company to reacquire up to 3.9% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s management believes its shares are undervalued.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were issued a $0.60 dividend. The ex-dividend date of this dividend was Friday, May 15th. This represents a $2.40 annualized dividend and a dividend yield of 0.8%. Cencora’s payout ratio is presently 18.40%.

Insider Buying and Selling at Cencora

In other news, Director Lauren M. Tyler purchased 550 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were acquired at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the completion of the purchase, the director directly owned 4,359 shares in the company, valued at $1,177,932.57. The trade was a 14.44% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.38% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several analysts recently commented on COR shares. Evercore set a $360.00 price target on shares of Cencora in a research report on Wednesday, April 8th. Citigroup lowered their price objective on shares of Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Wells Fargo & Company dropped their price objective on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a research note on Monday, May 11th. Barclays reduced their target price on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a report on Wednesday, June 10th. Finally, UBS Group raised their price target on Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Eleven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Cencora currently has an average rating of “Moderate Buy” and a consensus target price of $367.75.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.